Cystic Fibrosis
Conditions
Keywords
Cystic fibrosis, Pseudomonas aeruginosa, biofilm, antibiotic susceptibility testing, pediatrics
Brief summary
The purpose of this study is to determine whether choosing antibiotics based on a biofilm antimicrobial susceptibility assay rather than a conventional planktonic antimicrobial susceptibility assay to treat CF patients with chronic P. aeruginosa infection with an acute pulmonary exacerbation is a safe intervention that will result in improved microbiological and clinical outcomes and decrease markers of pulmonary inflammation.
Detailed description
Cystic fibrosis (CF) is the most common fatal genetic condition in the Caucasian population and affects over 3,000 Canadians. Respiratory failure caused by chronic pulmonary infection is the primary cause of death in CF patients. The improved life expectancy of CF patients in the past several decades is due in part to the more aggressive use of antibiotics in the treatment of respiratory infections. However, there is currently no antimicrobial susceptibility assay that can predict which antibiotics will result in improved patient outcomes. Since Pseudomonas aeruginosa is known to grow as a resistant biofilm in the CF lung, antimicrobial susceptibility testing based on biofilm growth of P. aeruginosa may lead to different antibiotic choices that significantly decrease the pulmonary bacterial density of P. aeruginosa. A biofilm antimicrobial susceptibility assay thus has the ability to change the way antibiotics are chosen to treat CF patients and result in improved lung function and longer lives for all CF patients.
Interventions
OTHERConventional antimicrobial susceptibility testing
Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.
OTHERBiofilm antimicrobial susceptibility testing
Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
Sponsors
The Hospital for Sick Children
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Diagnosis of CF based on the following: sweat chloride \> 60 mEq/L or genotype with 2 identifiable mutations consistent with CF; and one or more clinical features consistent with CF * Chronically infected with P. aeruginosa (\>50% of respiratory specimens positive for P. aeruginosa in the 24 months prior to screening) * Able to produce sputum (expectorated or induced) * Able to reproducibility perform pulmonary function testing * Written informed consent provided
Exclusion criteria
* Sputum culture negative for P. aeruginosa or with a density of less that 10\^5 CFU/g at screening * Sputum culture positive for Burkholderia cepacia at screening * History of B. cepacia positive respiratory culture within 24 months prior to screening * Use of antibiotics other than those prescribed by the principal investigator * History of allergy (urticarial rash, diffuse erythroderma, serum sickness) to more than two groups of antibiotics (aminoglycosides, penicillins, cephalosporins, monobactams, macrolides, or quinolones) that are a therapeutic option * History of anaphylaxis or other life threatening complication to any antibiotic in the six groups that are a therapeutic option * Post lung transplantation or listed for lung transplantation * Pregnancy * A septic or clinically unstable patient * Presence of a condition or abnormality that in the opinion of an investigator would compromise the safety of the patient or the quality of the data
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients in the intervention arm versus the control arm who have ≥ 3 log drop in colony forming units (CFUs) of P. aeruginosa in sputum. | Measured at day 0 and day 14 of antibiotic treatment and at the 1 month follow-up visit |
Secondary
| Measure | Time frame |
|---|---|
| The change in pulmonary function tests, including forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and maximal midexpiratory flow rate (FEF25-75) in the intervention arm versus the control arm | Measured at day 0, day 7, and day 14 of antibiotic treatment and at the 1 month follow-up visit |
| The time to subsequent acute pulmonary exacerbation in the intervention arm versus the control arm | 1 year following the completion of antibiotic therapy |
| The change in the cumulative score on a quality of life questionnaire in the intervention arm versus the control arm | Measued at day 0 and day 14 of antibiotic treatment and at the 1 month follow-up visit |
| The change in the measurement of markers of pulmonary inflammation (neutrophil counts, neutrophil elastase and IL-8 levels in sputum) in the intervention arm versus the control arm. | Meaured at day 0 and day 14 of antibiotic treatment and at the 1 month follow-up visit |
Countries
Canada
Outcome results
None listed